Crestor and Sildenafil Interaction: What Prescribers and Patients Should Know

Why Rosuvastatin and Sildenafil Are Pharmacokinetically Compatible

Rosuvastatin differs from older statins in one critical way: it bypasses CYP3A4-mediated metabolism almost entirely. According to the FDA-approved Crestor label, rosuvastatin undergoes limited metabolism, with approximately 10% cleared through CYP2C9 and the remainder excreted unchanged in feces [1]. This stands in contrast to simvastatin and lovastatin, which depend heavily on CYP3A4 for biotransformation and carry well-documented interaction risks with CYP3A4 inhibitors.

Sildenafil is metabolized primarily by CYP3A4 and to a lesser extent by CYP2C9, as stated in the Viagra prescribing information [2]. Because rosuvastatin neither inhibits nor induces CYP3A4, it does not alter sildenafil plasma concentrations. The minor CYP2C9 overlap between the two drugs has not produced any measurable change in exposure in pharmacokinetic modeling or clinical practice.

This matters. Patients prescribed rosuvastatin for dyslipidemia and sildenafil for erectile dysfunction or pulmonary arterial hypertension can take both without concern for competitive enzyme inhibition raising drug levels to toxic thresholds.

The CYP3A4 Distinction: Why Statin Choice Matters

Not all statins behave the same when paired with PDE5 inhibitors. Simvastatin 80 mg, for example, carries an FDA boxed warning against co-administration with strong CYP3A4 inhibitors due to the risk of myopathy and rhabdomyolysis [3]. A pharmacokinetic analysis published in Clinical Pharmacology & Therapeutics demonstrated that CYP3A4 inhibition can increase simvastatin AUC by up to 12-fold, a magnitude that pushes muscle toxicity risk from theoretical to real [3].

Rosuvastatin avoids this entirely. Its primary uptake into hepatocytes relies on organic anion-transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP), not CYP3A4 [1]. A 2016 review in the European Journal of Clinical Pharmacology confirmed that rosuvastatin's interaction profile is among the most favorable of all marketed statins precisely because of this metabolic independence [4].

Sildenafil itself is not a strong CYP3A4 inhibitor. It is a substrate. So the interaction concern runs in one direction only: drugs that inhibit CYP3A4 can raise sildenafil levels. Rosuvastatin does not do this.

Blood Pressure: The Pharmacodynamic Consideration Worth Noting

While the pharmacokinetic story is clean, clinicians should consider the pharmacodynamic overlap. Sildenafil lowers systolic blood pressure by an average of 8.4 mmHg and diastolic blood pressure by 5.5 mmHg, as reported in the original sildenafil efficacy trial published in the New England Journal of Medicine [5]. These effects are transient, typically resolving within 4 to 6 hours, but they become clinically relevant in patients already on antihypertensives.

Rosuvastatin has no direct vasodilatory mechanism. Some statin pleiotropic effects, including improved endothelial nitric oxide bioavailability, may produce modest blood pressure reductions over months of therapy. A meta-analysis of 40 trials in the American Journal of Cardiology found that statins lowered systolic blood pressure by a mean of 2.6 mmHg, an effect too small to produce symptomatic hypotension on its own [6].

The practical concern is narrow. A patient taking rosuvastatin, an alpha-blocker, and an ACE inhibitor who adds sildenafil may experience additive hypotension. The statin is the least contributing factor in that scenario, but clinicians should still ask about the full medication list before co-prescribing.

Who Needs Monitoring and Who Does Not

The American College of Cardiology's 2018 Cholesterol Clinical Practice Guideline does not flag PDE5 inhibitor co-administration as a monitoring trigger for statin therapy [7]. Standard monitoring applies: fasting lipid panel at baseline and 4 to 12 weeks after initiation, hepatic transaminase measurement if symptoms suggest hepatotoxicity, and creatine kinase testing only when myalgia develops.

For sildenafil, the 2018 AUA guideline on erectile dysfunction recommends a cardiovascular risk assessment before prescribing PDE5 inhibitors to any man with known atherosclerotic disease [8]. Patients already on a statin likely have established ASCVD or significant risk factors, which means the cardiovascular fitness assessment is the more important clinical step than any drug interaction check.

Three patient populations warrant closer attention:

Patients on high-dose rosuvastatin (40 mg) with renal impairment. The Crestor label restricts the 40 mg dose in patients with eGFR <30 mL/min/1.73m² [1]. Sildenafil clearance also decreases with renal impairment. While no pharmacokinetic interaction exists, both drugs may accumulate independently, and lower starting doses of sildenafil (25 mg) are reasonable in this group.

Patients co-prescribed OATP1B1 inhibitors. Cyclosporine, certain protease inhibitors, and gemfibrozil inhibit OATP1B1 and can raise rosuvastatin levels 5- to 7-fold [1]. If a patient on one of these drugs also takes sildenafil, the myopathy risk comes from the OATP1B1 inhibitor-rosuvastatin interaction, not from sildenafil. Still, the clinical picture can be confusing if the patient reports muscle pain.

Patients on nitrates. This is not a rosuvastatin issue. Sildenafil is absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) due to the risk of severe, potentially fatal hypotension [2]. The JUPITER trial (N=17,802) demonstrated that rosuvastatin-treated patients had a 44% reduction in major cardiovascular events, and many of these patients were also candidates for nitrate therapy at some point [9]. A prescriber managing such a patient must address the nitrate-sildenafil contraindication independently from the statin regimen.

Rhabdomyolysis Risk: What the Evidence Actually Shows

No published case report in PubMed links rosuvastatin-sildenafil co-use to rhabdomyolysis. A 2019 systematic review of statin-associated muscle symptoms in the Annals of Internal Medicine found that nocebo effects account for a large proportion of reported statin myalgia, with true statin-attributable muscle toxicity occurring in roughly 1 in 10,000 patient-years at moderate doses [10].

The pharmacological basis for rhabdomyolysis requires high intramyocyte statin concentrations, which occur when hepatic uptake or clearance is impaired. Sildenafil does neither. It does not inhibit OATP1B1. It does not inhibit BCRP. It does not inhibit CYP2C9 at therapeutic concentrations. The theoretical pathway to sildenafil-mediated rosuvastatin myotoxicity simply does not exist in current pharmacological models.

By contrast, the combination of simvastatin with erythromycin, itraconazole, or HIV protease inhibitors has produced documented rhabdomyolysis cases precisely because those inhibitors block CYP3A4, the pathway simvastatin depends on [3]. Rosuvastatin's avoidance of CYP3A4 is a structural safety advantage that extends to all CYP3A4 substrates, including sildenafil.

Dose Adjustments: When They Apply and When They Do Not

For the standard clinical scenario of rosuvastatin 5 to 20 mg daily combined with sildenafil 25 to 100 mg as needed, no dose adjustment is required. The Endocrine Society and ACC/AHA lipid guidelines do not recommend any statin dose modification based on PDE5 inhibitor use [7].

Dose adjustments become relevant only when a third drug enters the equation. The rosuvastatin FDA label specifies the following maximum doses when co-prescribed with known interacting drugs: 5 mg with cyclosporine, 10 mg with gemfibrozil, 10 mg with atazanavir/ritonavir, and 20 mg with other protease inhibitor combinations [1]. If a patient on one of these restricted regimens also uses sildenafil, the dose ceiling applies because of the OATP1B1 or BCRP interaction, not because sildenafil adds incremental risk.

For sildenafil, dose reduction to 25 mg is recommended when co-prescribed with strong CYP3A4 inhibitors such as ketoconazole, ritonavir, or erythromycin [2]. Rosuvastatin is not a CYP3A4 inhibitor, so this reduction does not apply to the rosuvastatin-sildenafil pair.

Patient Counseling Points for Combined Use

Patients should hear three specific messages when prescribed both drugs:

First, the combination is safe from a drug interaction standpoint. Many patients taking a statin for cholesterol and sildenafil for erectile dysfunction worry about "overloading the liver." The metabolic pathways are distinct, and rosuvastatin's hepatic processing does not compete with sildenafil's.

Second, the timing of dosing does not need to be separated. Some patients ask whether they should space rosuvastatin and sildenafil apart. There is no pharmacokinetic rationale for doing so. Rosuvastatin can be taken at any consistent time of day, and sildenafil is taken as needed 30 to 60 minutes before sexual activity.

Third, the one absolute contraindication is nitrates. Dr. Robert Kloner, a cardiologist at the Keck School of Medicine, stated in a review in Circulation that "the contraindication of PDE5 inhibitors with nitrates remains absolute, regardless of other medications the patient may be taking" [11]. Patients should understand that the statin is not the concern. Nitrates are.

How Rosuvastatin Compares to Other Statins for PDE5 Inhibitor Compatibility

Among commonly prescribed statins, rosuvastatin and pravastatin have the lowest interaction potential with CYP3A4 substrates including sildenafil. Pravastatin is not metabolized by any CYP enzyme to a significant degree and is cleared by sulfation [12]. Rosuvastatin's minimal CYP2C9 involvement places it in a similar low-risk category.

Atorvastatin, while partially metabolized by CYP3A4, has a large therapeutic window and has not been linked to clinically significant interactions with sildenafil in published literature. The ASCOT-LLA trial (N=10,305) used atorvastatin 10 mg in a hypertensive population likely to include PDE5 inhibitor users, and no excess myopathy signal emerged [13].

Simvastatin and lovastatin carry the highest risk. A 2012 FDA safety communication specifically restricted simvastatin 80 mg due to myopathy concerns amplified by CYP3A4 inhibition [3]. For patients on a CYP3A4-dependent statin who are starting sildenafil, switching to rosuvastatin eliminates this interaction entirely.

The choice between rosuvastatin 10 mg and atorvastatin 20 mg (approximately equivalent LDL-lowering potency) may be influenced by this interaction profile in patients taking multiple CYP3A4-metabolized medications. A pharmacist medication therapy management review should flag this consideration.